Guggenheim Capital’s Ascendis Pharma A/S ASND Stock Holding History

Guggenheim Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Sell	1,542 -7,740	-83%	-$1.81M	﹤0.01%	1376
2026 Q1	$2.12M	Buy	9,282 +2,548	+38%	+$571K	0.02%	683
2025 Q4	$1.44M	Buy	6,734 +1,428	+27%	+$295K	0.01%	776
2025 Q3	$1.05M	Sell	5,306 -929	-15%	-$173K	0.01%	902
2025 Q2	$1.08M	Sell	6,235 -819	-12%	-$133K	0.01%	865
2025 Q1	$1.1M	Sell	7,054 -195	-3%	-$27.9K	0.01%	846
2024 Q4	$998K	Buy	7,249 +5,218	+257%	+$686K	0.01%	922
2024 Q3	$303K	Buy	2,031 +217	+12%	+$29.3K	﹤0.01%	1611
2024 Q2	$247K	Buy	+1,814	New	+$247K	﹤0.01%	1704
2022 Q4	–	Sell	-2,571	Closed	-$265K	–	1915
2022 Q3	$265K	Buy	+2,571	New	+$244K	﹤0.01%	1704
2022 Q2	–	Sell	-2,008	Closed	-$236K	–	2050
2022 Q1	$236K	Buy	2,008 +135	+7%	+$15.6K	﹤0.01%	1981
2021 Q4	$252K	Buy	1,873 +562	+43%	+$83.6K	﹤0.01%	1951
2021 Q3	$209K	Buy	+1,311	New	+$179K	﹤0.01%	2050

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Guggenheim Capital's ASND Position: Q2 2026 in Review

Guggenheim Capital reduced its Ascendis Pharma A/S (ASND) stake by 83% in Q2 2026, selling an estimated $1.81M and leaving 1,542 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Guggenheim Capital first reported a position in ASND in Q3 2021 and has held it in 13 quarters since. The position peaked at $2.12M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Guggenheim Capital held 1,542 shares of Ascendis Pharma A/S worth $411K as of Q2 2026.
Guggenheim Capital sold 7,740 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.81M.
Ascendis Pharma A/S made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1376 holding.
Guggenheim Capital first reported a position in Ascendis Pharma A/S in Q3 2021 and has held it in 13 quarters since.
Guggenheim Capital's Ascendis Pharma A/S position peaked at $2.12M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.